Eagle Pharmaceuticals IncNASDAQ:EGRXNASDAQ FSI:E. Delinquent (Issuer missed regulatory filing deadline)
- LAST PRICE4.2400
- TODAY'S CHANGE (%)-0.3100 (-6.8132%)
- Bid / Lots4.1500/ 1
- Ask / Lots5.0000/ 6
- Open / Previous Close4.5000 / 4.5500
- Day Range
- 52 Week Range
- Volume130,193
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EGRX |
|---|---|---|
| 09:32 ET | 395 | 4.5 |
| 09:39 ET | 1100 | 4.49 |
| 09:43 ET | 600 | 4.46 |
| 09:52 ET | 1965 | 4.42 |
| 09:54 ET | 400 | 4.43 |
| 10:03 ET | 100 | 4.36 |
| 10:08 ET | 100 | 4.36 |
| 10:10 ET | 2000 | 4.44 |
| 10:12 ET | 1500 | 4.45 |
| 10:14 ET | 500 | 4.39 |
| 10:15 ET | 100 | 4.37 |
| 10:17 ET | 1400 | 4.46 |
| 10:19 ET | 100 | 4.375 |
| 10:24 ET | 200 | 4.46 |
| 10:28 ET | 700 | 4.45 |
| 10:30 ET | 100 | 4.3925 |
| 10:32 ET | 200 | 4.45 |
| 10:33 ET | 400 | 4.385 |
| 10:37 ET | 100 | 4.36 |
| 10:42 ET | 1900 | 4.4 |
| 10:46 ET | 100 | 4.36 |
| 10:50 ET | 100 | 4.36 |
| 10:51 ET | 800 | 4.35 |
| 10:53 ET | 443 | 4.35 |
| 10:55 ET | 100 | 4.395 |
| 10:57 ET | 100 | 4.3325 |
| 11:02 ET | 1900 | 4.36 |
| 11:04 ET | 2037 | 4.33 |
| 11:06 ET | 200 | 4.35 |
| 11:09 ET | 100 | 4.305 |
| 11:13 ET | 100 | 4.305 |
| 11:15 ET | 600 | 4.32 |
| 11:18 ET | 300 | 4.3 |
| 11:20 ET | 200 | 4.337 |
| 11:22 ET | 100 | 4.3 |
| 11:26 ET | 100 | 4.3 |
| 11:27 ET | 100 | 4.33 |
| 11:31 ET | 1001 | 4.34 |
| 11:33 ET | 700 | 4.35 |
| 11:40 ET | 100 | 4.315 |
| 11:44 ET | 100 | 4.325 |
| 11:45 ET | 100 | 4.36 |
| 11:47 ET | 100 | 4.36 |
| 11:49 ET | 100 | 4.315 |
| 11:54 ET | 100 | 4.305 |
| 12:00 ET | 1700 | 4.2995 |
| 12:02 ET | 100 | 4.32 |
| 12:03 ET | 100 | 4.295 |
| 12:05 ET | 200 | 4.325 |
| 12:12 ET | 100 | 4.325 |
| 12:18 ET | 100 | 4.325 |
| 12:20 ET | 400 | 4.31 |
| 12:21 ET | 200 | 4.33 |
| 12:27 ET | 800 | 4.325 |
| 12:30 ET | 100 | 4.325 |
| 12:32 ET | 200 | 4.34 |
| 12:34 ET | 282 | 4.35 |
| 12:36 ET | 100 | 4.305 |
| 12:39 ET | 100 | 4.33 |
| 12:41 ET | 300 | 4.35 |
| 12:48 ET | 404 | 4.33 |
| 12:54 ET | 100 | 4.305 |
| 12:59 ET | 100 | 4.3 |
| 01:06 ET | 200 | 4.28 |
| 01:15 ET | 1961 | 4.32 |
| 01:17 ET | 400 | 4.32 |
| 01:21 ET | 1663 | 4.31 |
| 01:24 ET | 236 | 4.31 |
| 01:26 ET | 5332 | 4.27 |
| 01:28 ET | 5947 | 4.28 |
| 01:30 ET | 1300 | 4.295 |
| 01:32 ET | 100 | 4.305 |
| 01:33 ET | 100 | 4.33 |
| 01:39 ET | 400 | 4.36 |
| 01:42 ET | 300 | 4.39 |
| 01:48 ET | 200 | 4.4 |
| 01:50 ET | 1000 | 4.36 |
| 01:51 ET | 700 | 4.38 |
| 01:53 ET | 2500 | 4.31 |
| 01:55 ET | 5240 | 4.39 |
| 01:57 ET | 732 | 4.3608 |
| 02:02 ET | 100 | 4.38 |
| 02:04 ET | 200 | 4.36 |
| 02:08 ET | 200 | 4.33 |
| 02:09 ET | 1746 | 4.355 |
| 02:11 ET | 1234 | 4.34 |
| 02:20 ET | 100 | 4.31 |
| 02:24 ET | 100 | 4.31 |
| 02:29 ET | 100 | 4.31 |
| 02:36 ET | 200 | 4.335 |
| 02:40 ET | 100 | 4.31 |
| 02:42 ET | 1934 | 4.305 |
| 02:44 ET | 557 | 4.29 |
| 02:45 ET | 926 | 4.3 |
| 02:49 ET | 100 | 4.29 |
| 02:54 ET | 100 | 4.31 |
| 03:00 ET | 100 | 4.33 |
| 03:07 ET | 509 | 4.3162 |
| 03:09 ET | 100 | 4.33 |
| 03:14 ET | 100 | 4.31 |
| 03:18 ET | 909 | 4.2931 |
| 03:20 ET | 167 | 4.33 |
| 03:21 ET | 100 | 4.29 |
| 03:23 ET | 200 | 4.33 |
| 03:25 ET | 100 | 4.29 |
| 03:27 ET | 100 | 4.29 |
| 03:30 ET | 7852 | 4.27 |
| 03:32 ET | 900 | 4.24 |
| 03:36 ET | 400 | 4.26 |
| 03:38 ET | 300 | 4.24 |
| 03:39 ET | 100 | 4.26 |
| 03:41 ET | 100 | 4.25 |
| 03:43 ET | 400 | 4.26 |
| 03:45 ET | 969 | 4.22 |
| 03:48 ET | 2997 | 4.22 |
| 03:50 ET | 600 | 4.2 |
| 03:52 ET | 1495 | 4.22 |
| 03:54 ET | 2855 | 4.21 |
| 03:56 ET | 100 | 4.19 |
| 03:57 ET | 11216 | 4.3 |
| 03:59 ET | 408 | 4.24 |
Apr 17, 2024
Lifshitz Law PLLC Announces Investigations of InMode Ltd. (NASDAQ: INMD), General Motors Company (NYSE: GM), Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX), and Driven Brands Holdings Inc. (NASDAQ: DRVN), from 6:02AM ET on Wednesday Apr 17, 2024 by Dow Jones
6:02AM ET on Wednesday Apr 17, 2024 by Dow Jones
Apr 15, 2024
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida, from 7:00AM ET on Monday Apr 15, 2024 by Dow Jones
7:00AM ET on Monday Apr 15, 2024 by Dow Jones
Apr 12, 2024
Apr 5, 2024
Lifshitz Law PLLC Announces Investigations of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX), ON Semiconductor Corporation (NASDAQ:ON), Mercury Systems, Inc. (NASDAQ:MRCY), and The Lovesac Company (NASDAQ:LOVE), from 1:02PM ET on Friday Apr 05, 2024 by Dow Jones
1:02PM ET on Friday Apr 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Eagle Pharmaceuticals Inc | 59.1M | 4.7x | -4.75% |
Medicine Man Technologies Inc | 50.0M | -0.4x | --- |
Shengtai Pharmaceutical Inc | 10.0 | 0.0x | --- |
Lotus Pharmaceuticals Inc | 13.5M | 0.1x | +42.39% |
Cumberland Pharmaceuticals Inc | 22.8M | -3.8x | --- |
Scilex Holding Co | 141.3M | -0.7x | --- |
Company Information
Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The Company also has a research and development facility in Cambridge, Massachusetts. The Company has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Company’s subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.
Contact Information
- Headquarters
- 50 Tice Boulevard, Suite 315WOODCLIFF LAKE, NJ, United States 07677
- Phone
- 201-326-5300
- Fax
- 302-655-5049
Executives
- Interim Executive Chairman of the Board, Interim Principal Executive Officer
- Michael Graves
- Interim Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
- Steven Ratoff
- Independent Director
- Luciana Borio
- Independent Director
- Richard Edlin
- Independent Director
- Robert Glenning
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $59.1M |
|---|---|
Revenue (TTM) | $257.6M |
Shares Outstanding | 13.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.43 |
EPS | $0.91 |
Book Value | $17.94 |
P/E Ratio | 4.7x |
Price/Sales (TTM) | 0.2 |
Price/Cash Flow (TTM) | 1.8x |
Operating Margin | 13.98% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
